δ-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid

Occupational and Environmental Medicine

Volumn 54, Issue 4, 1997, Pages 241-246

  Schwartz, Brian S ^a,b,c,f   Lee, Byung Kook ^d   Stewart, Walter ^a,b   Sithisarankul, Pornchai ^a   Strickland, Paul T ^a   Ahn, Kyu Dong ^d   Kelsey, Karl ^e  

^a Dept of Environ Health Sciences   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Soonchunhyang University   (South Korea)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

chelating agents; dimercaptosuccinic acid; lead; aminolevulinic acid dehydratase genotype

Indexed keywords

AMINOLEVULINIC ACID; LEAD; PORPHOBILINOGEN SYNTHASE; PROTOPORPHYRIN ZINC; SUCCIMER;

ADULT; ARTICLE; BATTERY INDUSTRY; CHELATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG URINE LEVEL; GENOTYPE; HUMAN; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; TOXICOKINETICS;

EID: 0030892932     PISSN: 13510711     EISSN: None     Source Type: Journal    
DOI: 10.1136/oem.54.4.241     Document Type: Article

References (34)

1. Marcus A. The body burden of lead: comparison of mathematical models for accumulation. Environ Res 1979; 19:79-90.
2. O'Flaherty EJ. Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. Toxicol Appl Pharmacol 1993;118:16-29.
3. Raghavan SRV, Culver BD, Gonick HC. Erythrocyte lead-binding protein after occupational exposure: 1 relationship to lead toxicity. Environ Res 1980;2:264-70.
4. Lolin Y, O'Gorman P. An intra-erythrocytic low molecular weight lead-binding protein in acute and chronic lead exposure and its possible protective role in lead toxicity. Ann Clin Biochem 1988;25:688-97.
5. 2Pb with constituents of erythrocytes. Health Phys 1973; 25:34-42.
6. Ong CN, Lee WR. High affinity of lead for fetal haemoglobin. Br J Ind Med 1980;37:292-8.
7. Ziemsen B, Angerer J, Lehnen G, et al. Polymorphism of delta-aminolevulinic acid dehydratase in lead-exposed workers. Int Arch Occup Environ Health 1986;58:245-7.
8. Wetmur JG, Lehnen G, Desnick RJ. The δ-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with the 1-2 and 2-2 isozymes. Environ Res 1991;56: 109-19.
9. Wetmur JG, Bishop DF, Cantelmo C, Desnick RJ. Human δ-aminolevulate dehydratase: nucleotide sequence of a full length cDNA clone. Proc Natl Acad Sci USA 1986; 83:7703-7.
10. Potluri VR, Astrin KH, Wetmur JK, et al. Human δ-aminolevulinate dehydratase: chromosomal localization to 9q34 by in situ hybridization. Hum Genet 1987;76: 236-9.
11. Battistuzzi G, Petrucci R, Silvagni L, et al. δ-Aminolevulinate dehydratase: a new genetic polymorphism in man. Ann Hum Genet 1981;45:223-9.
12. 2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 1991;49:757-63.
13. Bellinger D, Hu H, Titlebaum L, Needleman HL. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health 1994;49:98-105.
14. Schwartz BS, Lee B-K, Stewart W, Ahn K-D, Springer K, Kelsey K. Associations of δ-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Am J Epidemiol 1995;142:738-45.
15. Smith CM, Wang X, Hu H, Kelsey KT. A polymorphism in the δ-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 1995;103:248-53.
16. Lee B-K, Schwartz BS, Stewart W, Ahn K-D. Urinary lead excretion after DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med 1995; 52:13-9.
17. Brangstrup Hansen JP, Døssing M, Paulev P-E. Chelatable lead body burden (by calcium-disodium EDTA) and blood lead concentration in man. J Occup Med 1981; 23:39-43.
18. Araki S, Aono H, Murata K. Mobilisation of heavy metals into the urine by CaEDTA: relation to erythrocyte and plasma concentrations and exposure indicators. Br J Ind Med 1986;43:636-41.
19. Tell I, Somervaille IJ, Nilsson U, Bensryd I, Schütz A, Chettle DR, et al. Chelated lead and bone lead. Scand J Work Environ Health 1992;18:113-9.
20. Alessio L, Castoldi MR, Monelli O, Toffoletto F, Zocchetti C. Indicators of internal dose in current and past exposure to lead. Int Arch Occup Environ Health 1979;44: 127-32.
21. Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther 1989;45:520-6.
22. Maiorino RM, Akins JM, Blaha K, Carter DE, Aposhian HV. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther 1990;254:570-7.
23. Maiorino RM, Aposhian MM, Xu Z-F, Li Y, Polt RL, Aposhian HV. Determination and metabolism of dithiol chelating agents. XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat. J Pharmacol Exp Ther 1993; 267:1221-6.
24. Cory-Slechta DA. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J Pharmacol Exp Ther 1988;246:84-91.
25. Cory-Slechta DA, Weiss B, Cox C. Mobilization and redistribution of lead over the course of CaEDTA chelation therapy. J Pharmacol Exp Ther 1987;243:804-13.
26. Aposhian HV, Aposhian MM. Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Ann Rev Pharmacol Toxicol 1990;30:279-306.
27. Graziano JH, Siris ES, Lolacono N, Silverberg SJ, Turgeon L. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985;37:431-8.
28. Sithisarankul P, Schwartz BS, Lee B-K, Kelsey KT, Strickland PT. Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. Am J Ind Med 1997;(in press).
29. Tomokuni K, Ichiba M, Fujishiro K. Interrelation between urinary δ-aminolevulinic acid (ALA), serum ALA, and blood lead in workers exposed to lead. Ind Health 1993; 31:51-7.
30. Tomokuni K, Ichiha M, Hirai Y. HPLC micro-method for determining δ-aminolevulinic acid in plasma. Clin Chem 1993;39:169-70.
31. Tomokuni K, Ichiba M, Hirai Y. Measurement of urinary δ-aminolevulinic acid (ALA) by fluorometric HPLC and colorimetric methods. Ind Health 1992;30:119-28.
32. Kneip TJ, Crable JV. Methods for biological monitoring: a manual for assessing human exposure to hazardous substances. Washington, DC: American Public Health Association, 1988:193-7.
33. Kneip TJ, Crable JV. Methods for biological monitoring: a manual for assessing human exposure to hazardous substances. Washington, DC: American Public Health Association, 1988:199-201.
34. Gibson KD, Neuberger A, Scott JJ. The purification and properties of δ-aminolaevulinic acid dehydrase. Biochem J 1955;61:618-29.